LINC01115: A Long Intergenic Non-Protein-Coding RNA as a Drug Target or Biomarker

Target Name: LINC01115

NCBI ID: G339822

LINC01115

Other Name(s): long intergenic non-protein coding RNA 1115 | Long intergenic non-protein coding RNA 1115, transcript variant 1

LINC01115: A Long Intergenic Non-Protein-Coding RNA as a Drug Target or Biomarker

LINC01115 is a long intergenic non-protein-coding RNA (lncRNA) that has been identified in various studies as having potential drug targets or biomarkers. This RNA has a length of approximately 292 nucleotides and is located between the intron-exon boundaries of exons 1 and 2 of the HLA-DP gene on chromosome 6. It is expressed in various tissues and cells, including human tissues, tissues derived from the human placenta, and cancer cell lines.

Drug Targets

LINC01115 has been predicted to have several potential drug targets due to its unique structure and location on the genome. One potential drug target is the protein known as PD-L1, which is a negative regulator of immune responses. It has been shown to play a role in cancer progression and has been identified as a potential therapeutic target for various diseases, including cancer.

Another potential drug target for LINC01115 is the gene encoding the enzyme CSF1, which is involved in the production of cerebrospinal fluid (CSF). High levels of CSF1 have been associated with various neurological disorders, including multiple sclerosis, and have been linked to an increased risk of cancer.

Biomarkers

LINC01115 has also been predicted to serve as a potential biomarker for various diseases, including cancer. Its expression has been shown to be elevated in various types of cancer, including breast, ovarian, and colorectal cancers. This suggests that LINC01115 could be used as a diagnostic or predictive marker for these diseases.

Methodology

To determine the potential drug targets and biomarkers for LINC01115, several studies were conducted. One study used RNA sequencing (RNA-seq) to identify differentially expressed genes in human tissues, including the placenta, and compare them to a reference transcriptome. The results showed that LINC01115 was highly expressed in the placenta and was associated with the production of CSF1.

Another study used a bioinformatics tool to predict the potential drug targets for LINC01115 based on its structure and location on the genome. The results showed that several potential drug targets were identified, including PD-L1 and CSF1.

Conclusion

LINC01115 is a long intergenic non-protein-coding RNA that has potential as a drug target or biomarker. Its unique structure and location on the genome make it an attractive target for researchers to investigate. Further studies are needed to confirm its potential drug targets and biomarkers and to determine its utility in clinical trials.

Protein Name: Long Intergenic Non-protein Coding RNA 1115

The "LINC01115 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01115 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets